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1 INTRODUCTION 
 
1.1 Ischemia/reperfusion injury. Definition. 
Ischemia/reperfusion injury (I/R) is a tissue damage, which occurs during organ 
transplantation, thrombendarterectomy, myocardial ischemia and revascularisation (1). 
Lung I/R results in endothelial damage and dysfunction leading to the development of 
high permeability pulmonary edema. Clinical picture of lung I/R may vary from 
interstitial edema to multiple organ dysfunction syndrome. The pathogenesis of I/R is 
complex and involves both local and systemic inflammatory response characterized by 
oxidant production, complement activation, leukocyte–endothelial cell adhesion, 
transendothelial leukocyte migration, platelet–leukocyte aggregation, increased 
microvascular permeability and decreased endothelium dependent relaxation (1, 2). 
Over the past two decades, the role of free radicals and other inflammatory mediators 
in IR injury have been extensively investigated. However, these responses and 
mediators appear to contribute only in part to lung IR injury.  
 
1.2 Role of NO-cGMP signalling pathway in I/R injury  
Many authors reported an impairment of nitric oxide (NO) production under 
conditions of I/R to contribute significantly to endothelial dysfunction (3, 4). NO-
cGMP signalling pathway in the lung is involved in control of many biological 
functions involving vascular tone, microvascular permeability, and inhibition of 
neutrophil-endothelium interactions. NO is generated via oxidation of L-arginine by a 
family of three NO synthases (NOS): neuronal NOS (nNOS, type 1), inducible NOS 
(iNOS, type 2), and endothelial NOS (eNOS, type 3). All of the three NOS isoforms 
are expressed in the lung (5). In addition, in the lung a wide variety of cell types 
including epithelial cells, inflammatory cells, and endothelial cells express NOS (6). 
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However, there is little knowledge about their interaction and pathophysiologic 
relevance in I/R-associated inflammatory processes. 
Blockage of NOS has been shown to be both beneficial (7, 8) and deleterious (9) in 
the condition of I/R. Moreover, administration of NO, the product of NO synthase, 
produced ambiguous results. NO inhalation has been demonstrated to attenuate I/R 
lung injury in experimental (10) and clinical settings (11). However, other authors (12) 
reported that nitric oxide application after bilateral lung transplantation did not 
improve early graft dysfunction. In the randomized clinical trial (13) prophylactic NO 
administration had no effect on pulmonary edema formation and resolution following 
lung transplantation. Possible explanation for these differing results could be that 
different NO synthase isoforms have different functions and influence differently 
inflammatory reactions in the course of I/R. Indeed, whereas eNOS has been 
demonstrated to reduce inflammation (14), iNOS has been demonstrated to be 
involved in mediation of inflammation (15).  
 
1.2.1 Role of iNOS in I/R injury 
 Induction of high-output iNOS during I/R might lead to overproduction of NO and 
contribute to vascular damage. NO overproduction in an oxidant-rich environment is 
suggested to cause tissue injury by formation of toxic peroxynitrite (16). Activation of 
iNOS and excessive peroxynitrite formation have been demonstrated to contribute to 
I/R induced vascular dysfunction and selective iNOS inhibition prevented lungs from 
the dysfunction (17).  
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1.2.2 Role of eNOS in I/R injury  
eNOS has been demonstrated to be protective against ischemia reperfusion injury. 
Activation eNOS has been shown to attenuate post-ischemic inflammatory injury (18). 
Moreover, over-expression of eNOS in mice led to reduced infarct size after 
myocardial I/R (19). On the other hand, oxidative stress, as a result of I/R (20), can 
induce oxidation of cofactors like tetrahydrobiopterin (21) and therefore lead to eNOS 
uncoupling and switch from NO production to superoxide production (22). Indeed, 
eNOS uncoupling in diabetic transgenic mice has been demonstrated to exacerbate I/R 
induced liver injury (23). In contrast, other authors reported that eNOS is involved in 
development of vascular leakage in acute inflammation, and eNOS knock out (KO) 
mice are protected against the injury (24). 
 
1.2.3 Role of nNOS in I/R injury  
Role of nNOS in the development of lung I/R injury has not been studied intensively. 
However, this isoform has been shown to contribute to brain injury. Increased 
expression of nNOS has been demonstrated in the brain after I/R (25). The increased 
expression of nNOS led to increased cell death after reoxygenation in the model of 
cerebellar I/R (26). Moreover, selective nNOS inhibition reduced cerebral injury in 
preventive and curative therapeutic approaches (27). In model of myocardial I/R 
injury nNOS lacking mice developed infarct of the same size as their wild type 
counterparts did (28).  
 
1.2.4 Role of sGC in I/R injury  
Soluble guanylyl cyclase (sGC) is a downstream molecule in NO-cGMP signalling 
pathway. This enzyme is responsible for conversion of GTP to cGMP. The latter 
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messenger affects cGMP dependent phosphodiesterases, protein kinases, ion channels, 
thus exerting its effect. Enhancing the effect of sCG has been demonstrated to protect 
against I/R lung injury. Schütte et al. have revealed that inhibition of PDE5, which is 
responsible for degradation of cGMP, protects against I/R lung injury (29). 
Application of cGMP analogue 8-BrcGMP to organ preservation solution (30) has 
been shown to reduce lung damage. 
 
1.3 Role of NADPH oxidase in I/R injury 
In many studies the role of reactive oxygen species (ROS) in development of I/R 
injury has been demonstrated (31). There are many enzyme systems capable of ROS 
production in the cell, including mitochondrial respiratory chain, xanthine 
oxidoreductase, uncoupled NO synthase, and NADPH oxidase. Among them, NADPH 
oxidases are expressed in many cell types in the lung and produce large amounts of 
ROS. Indeed, I/R lung injury was associated with activation of NADPH oxidase (32). 
Moreover, inhibition of NADPH oxidase has been reported to be protective against 
vascular leakage in reperfused lungs (33). Mice lacking functional NADPH oxidase 
were protected against development of stroke (34). 
 
1.4 Interaction between NO-cGMP signalling pathway and NADPH oxidase 
Reactive oxygen species can not only induce tissue damage directly, by oxidizing 
variety of biomolecules, but also interfere with function of other signalling pathways. 
ROS could influence NO-cGMP signalling pathway via binding with NO, thereby 
limiting its bioavailability. This is underlying mechanism of endothelial dysfunction. 
Importance of this mechanism has been demonstrated for development of 
atherosclerosis (35), and stroke (36). In presence of large amounts of NO, reaction 
with superoxide leads to peroxynitrite formation, which in turn contributes to 
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oxidative damage. Less is known about the influence of NO-cGMP pathway on 
NADPH oxidases. It has been shown that NOS activation can inhibit NADPH oxidase 
via interfering with its assembly (37, 38) and changing its expression (39, 40). 
 
1.5 Introduction into NO-cGMP pathway 
 NO synthases consist of two catalytic domains: N-terminal oxygenase domain and C-
terminal reductase domain (Scheme 1). Oxygenase domain contains binding site for L-
arginine, heme and tetrahydrobiopterin (BH4), while reductase domain has binding 
sites for FAD, FMN and NADPH. These two catalytic domains are connected by a 
calmodulin binding site. Flavins mediate transfer of electrons from NADPH to the 
heme iron, bringing about NO production via oxidation of L-arginine to L-citrulline. 
BH4 is important for the electron shuttling process and effects the homodimeric 
conformation of NOS. NOS isoforms share approximately 50% of primary sequence 
homology, suggesting that they may differ from each other in regulatory aspects. 
 
1.5.1 Endothelial NO synthase 
eNOS is expressed primarily in endothelial cells but also in cardiac myocytes and 
platelets. In the lung eNOS expression was demonstrated in endothelial cells and 
bronchial epithelium (6). Regulation of eNOS activity is complex. Large variety of 
factors are known to regulate eNOS activity including shear stress, acetylcholine, 
bradykinin, histamine, VEGF, thrombin, estrogen. eNOS activity is regulated on the 
transcriptional level or by post-translational modifications (41). The latter include 
interactions like calcium-dependent calmodulin binding, post-translational 
modifications ( e.g. phosphorylation, acylation) as well as sub-cellular 
compartmentalization (42).  
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1.5.2 Neuronal NO synthase 
Neuronal NOS has been shown to be expressed in neurons. Additionally, other non-
neuronal cell types including: cardiac myocytes, skeletal myocytes, and the adventitia 
of a subset of neuronal blood vessels have been demonstrated to express nNOS (43). 
In the lung nNOS expression has been demonstrated in bodies and termini of non-
adrenergic non cholinergic nerves innervating airway and vascular smooth muscle 
cells (44) as well as in capillary endothelial cells (45). Regulation of nNOS is 
N CPDZ Arg   Heme BH4 FMN FMN FAD   NADPH
CaM
Zn2+
N CArg   Heme BH4 FMN FMN FAD   NADPH
CaM
Zn2+
Myr Palm
N CArg   Heme BH4 FMN FMN FAD   NADPH
CaM
Zn2+
Ca2+
Oxygenase domain Reductase domain
nNOS
160 kDa
eNOS
135 kDa
iNOS
130 kDa
 
Scheme 1. Structural domains of NOS enzymes: alignment of conserved regions of the NOS enzymes. 
Calmodulin (CaM), cofactor and substrate binding regions. Isoform specific features including membrane-
localizing PDZ (nNOSa and nNOSl), myristoylation (Myr) and palmitoylation (Palm) sites (eNOS) are also 
shown. Arg (l-arginine), BH4 (tetrahydrobiopterin), FAD (flavin adenine dinucleotide), FMN (flavin 
mononuclotide), NADPH (nicotinamide adenine dinucleotide phosphate), Zn2+ (zinc). 
Adopted with modifications from N. Mungrue, Acta Physiol Scand 2003, 179, 123–135 
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complex. It is regulated acutely through reversible calcium–calmodulin binding. Brain 
derived neurotrophic factor (BDNF) and glial derived neurotrophic factor (GDNF) 
were demonstrated to control expression of nNOS. Interesting and specific feature of 
nNOS is presence of variety spicing variants, which are expressed in different tissues 
(46). 
 
1.5.3 Inducible NO synthase 
Inflammation mediators have been demonstrated to induce expression of inducible 
NOS (iNOS, NOSII, NOS2) in many cell types including endothelial cells, smooth 
muscle cells, macrophages (47). 
Regulation of iNOS is calcium-insensitive. iNOS is predominantly regulated at 
expressional level. The expression of iNOS is upregulated by LPS, oxidative stress 
and variety of cytokines such as interleukin-1β (IL-1β), interferon-γ (IFN-γ) and 
tumor necrosis factor-α (TNF-α). Different inducers of iNOS activate different 
signaling pathways, leading either to enhanced transcription via nuclear factor kappa 
B (NF-kB), interferon regulatory factor-1 (IRF-1) or other transcription factors. 
Regulation of iNOS occurs also via modulation of mRNA stability. Kleinert et al. 
summarized in his recent review the latest advances in this field of research (48). 
 
1.5.4 Soluble guanylyl cyclase (sGC) 
There are two isoforms of guanylyl cyclase: particulate (pGC) and soluble (sGC). sGC 
is a main down stream target of nitric oxide. Therefore, in our work we will discuss 
only this isoform. Its expression has been demonstrated in the cytoplasm of almost all 
mammalian cells (49). 
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NO activates sGC via binding to heme group and changing its conformation. 
Conformational changes result in activation of the enzyme. Recently a novel NO-
independent sGC stimulation mechanism has been described. YC-1 and BAY 582667 
have been demonstrated to bind to α-subunit of sGC leading to its activation. This 
activation takes place even in absence of NO. In presence of the stimulators effect of 
NO is enhanced (50).  
 
1.6 Aim of the study 
Despite intensive research exact pathomechanisms of I/R syndrome remain unclear. 
Previous studies produced equivocal results about the role of NO synthases in 
mediation of I/R injury. NO synthase inhibition has been shown to reduce lung injury 
(7, 8, 51). However, reduced iNOS expression and reduced activity of NO-cGMP 
signalling pathway in the course of I/R have been described (52). On the other hand, 
upregulation of eNOS attenuated I/R induced lung injury (18). 
Although activation of sGC seems to be protective against I/R injury (30), exact 
mechanisms of the protective effect remain unclear. 
Aim of this study was to evaluate: 1) the role of different NO synthases in the 
mediation of I/R induced lung injury and 2) the role of NO-cGMP signalling pathway 
in the control of NADPH oxidase activity in the course of I/R lung injury. 
To answer these questions we applied the model of isolated perfused rabbit and mouse 
lung, because this model enables us to study processes taking place in the lung without 
regulatory influence of the whole body. We applied inhibitors of different NOS 
isoforms to determine contribution of different isoforms to development of I/R injury. 
Since inhibitors can display unspecific effects, mice with genetic depletion of eNOS 
and iNOS were employed. To reveal effects of NADPH oxidase, its stimulator and 
inhibitor were applied. 
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2 MATERIALS AND METHODS 
 
2.1 Applied substances 
All chemicals used were of analytical grade purity. Alphabetical list of used 
chemicals, reagents and consumables is provided in tables 1 and 2. 
 
Table 1. Alphabetical list of used substances. 
 
Substance Chemical name Company Catalogue 
number 
1400W N-(3-(Aminomethyl)benzyl) 
acetamidine . 2HCl 
Alexis ALX-270-
073-M005 
Apocynin 4′-Hydroxy-3′-
methoxyacetophenone 
Sigma-Aldrich-
Aldrich 
W508454 
BAY 41-2272  kindly provided by 
Dr. Stasch 
 
BYK 191023  Kindly provided 
by Altana Pharma 
 
Calcium 
chloride 
dehydrate 
CaCl2 x 2H2O Fluka Biochemika 21097 
Chelex 100  BioRad 
Laboratories 
142-2842 
CPH 1-hydroxy-3-carboxy-2,2,5,5-
tetramethylpyrrolidine 
Alexis ALX-430-
078-M250 
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Substance Chemical name Company Catalogue 
number 
D-(+)-glucose 
anhydrous 
 Fluka Biochemika 49139 
Deferoxamine 
mesylate 
 Sigma-Aldrich-
Aldrich 
D-9533  
Elektrolytlösung 
II/N (Krebs-
Henseleit buffer) 
 Serag-Wiessner 
KG 
218978 
Heparin  Ratiopharm GmbH 3029843 
Ketavet Ketamin hydrochloride Pfizer 72201-2 
L-NMMA NG-Monomethyl-L-arginine 
acetate salt 
Sigma-Aldrich-
Aldrich 
M7033 
Magnesium 
chloride 
hexahydrate 
MgCl2 x 6H2O Fluka Biochemika 63068 
PMA phorbol 12-myristrate 13-
acetate 
Sigma-Aldrich-
Aldrich 
P 8139-
10MG 
Potassium 
chloride 
KCl Fluka Biochemika 60128 
Potassium 
dihydro-
phosphate 
KH2PO4 Merk 74.873.1000 
Rompun 2% 
 
Xylazine hydrochloride Bayer Healthcare KP043Z 
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Substance Chemical name Company Catalogue 
number 
SOD superoxide dismutase from 
bovine erythrocytes 
Sigma-Aldrich-
Aldrich 
S-2515  
Sodium 
chloride 
NaCl Fluka Biochemika 71376 
 
Table 2. Consumables 
 
Consumables Supplier 
Single use syringes Inject Luer®, 
1ml, 2ml, 5ml, 10ml 
Braun, Melsungen, Germany 
BD Microlance needles 21G, 26G Becton Dickinson, Heidelberg, Germany 
Single use gloves Transaflex® Ansell, Surbiton Surrey, UK 
Gauze balls size 6 Fuhrman Verbandstoffe GmbH, Munich, 
Germany 
Napkins Tork, Mannheim, Germany 
Threads Nr. 12 Coats GmbH, Kenzingen, Germany 
Surgical threads non-absorbable 
ETHIBOND EXCEL®, size 5-0 
Ethicon GmbH, Norderstedt, Germany 
Surgical instruments Martin Medizintechnik, Tuttlingen, 
Germany 
Disposable feather scalpel Feather Safety Razor Co, Ltd, Osaka, 
Japan 
Pipette tips, blue, yellow, white EPPENDORF, Hamburg, Germany 
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Consumables Supplier 
Tygon® lab tubing 3603 Cole-Parmer Instruments Company, 
Vernon Hills, Illinois, USA 
Tracheal cannula Customer-made 
Cannula for pulmonary artery 
catheterisation 
Customer-made 
Cannula for left heart 
catheterisation 
Customer-made 
Combi-Stopper Intermedica GmbH Klein-Winternheim, 
Germany 
Combitrans Monitoring-Set B.Braun Melsungen AG, Melsungen, 
Germany 
Haematocrit sealing compound Blaubrand; Brand GmbH, Wertheim, 
Germany 
Filter papers Whatman, Schleicher & Schuell GmbH, 
Dassel, Germany 
Steritop Filter GP Express 0.22 µm Millipore, Eschborn, Germany 
 
2.2 Animals  
Male New Zealand Wight rabbits (body weight 2.8-3.5 kg) were used. WT C57BL/6J 
mice were purchased from Charles River Laboratory (Sulzfeld, Germany). iNOS and 
eNOS knockout (KO) mice were purchased from Jackson Laboratories (Bar Harbor, 
USA). All mice used in the experiments were male, 2 to 3 months of age, weighing 24 
to 28 g each. Animals were provided food and water ad libitum. Animals were kept 
under pathogen free conditions. All animals received humane care in compliance with 
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the “Principles of Laboratory Animal Care” and the Guide for the Care and Use of 
Laboratory Animals, published by the National Institutes of Health (NIH publication 
86-23, revised 1985). 
 
2.3 Isolated rabbit lung model.  
2.3.1 Setup of isolated perfused rabbit lung 
The model of isolated perfused and ventilated rabbit lung is depicted in the scheme 2. 
Devices and systems employed for the setup are listed in the table 4. The lung is 
canulated via pulmonary artery and left atrium and perfused in a recirculating system. 
Perfusion is flow-constant. Ventilation enables application of different gas mixtures. 
Ventilation is volume-constant. The lung is placed in warmed and humidified jacket. 
The model offers the opportunity to study specific pulmonary functions (53). This 
model possesses many advantages. It enables to determine physiological parameters, 
cells of the organ remain in their physiological and anatomical environment 
containing cell-to-cell contacts and native extracellular matrix. To the same time, 
 
 
Scheme 2. Schematic 
presentation of the 
model of isolated 
perfused rabbit lung. 
Abbreviations: A/D 
converter – analog-to-
digital converter, FT – 
force transducer, LV – 
left ventricle, PA – 
pulmonary artery. 
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controlling mechanisms of the organism are excluded. An investigator may retain 
control over several parameters. Limitation of this model is short duration of the 
experiment, since lungs deteriorate with time. Next limitation is deprivation of lymph 
drainage, which could contribute to fluid accumulation in the lung. 
 
2.3.2 Animal preparation 
Animals were anticoagulated with 1,000 U/kg of heparin and deeply anesthetized with 
ketamine and xylazine. A tracheostomy was performed, and the animals were room air 
ventilated with a tidal volume of 30 ml, a frequency of 30 breaths/min, and a positive 
end-expiratory pressure of 1 cm H2O. After a midsternal thoracotomy, catheters were 
inserted into the pulmonary artery and left atrium, and perfusion with sterile Krebs-
Henseleit buffer was started (content of Krebs-Henseleit buffer is provided in the table 
3). Sterilized perfusion circuit tubing was used throughout. In parallel with the onset 
of artificial perfusion, the gas supply was changed to a mixture of 5.3% CO2, 21% O2, 
73.7% N2 provided by Messer (Siegen, Germany). For the washout of blood, the 
perfusate was initially not recirculated. The lungs were removed from the thorax 
without interruption of ventilation and perfusion and were freely suspended from a 
force transducer for the monitoring of organ weight in a temperature-equilibrated, 
humidified chamber at 39°C. In a recirculating system, the flow was slowly increased 
to 100 ml/min (total volume 250 ml). Left atrial pressure was set at 2 mmHg 
(referenced at the hilum), and the whole perfusion system was equilibrated at 39°C. 
Additionally, the inspiration loop of the ventilation system was connected to a 
humidifier and heated to 39°C. 
Pressures in pulmonary artery and left atrium were registered with pressure 
transducers and transferred to computer. The capillary filtration coefficient (Kfc) was 
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determined gravimetrically from the slope of the lung weight gain curve induced by a 
7.5-mmHg step elevation of the venous pressure for 8 min as previously described 
(54). Lung weight gain was calculated as the difference in organ weight measured 
directly before and 5 min after each of these pressure elevation manoeuvres. 
 
Table 3. Content of Krebs-Henseleit buffer (Perfusate II/N) used for the setup of 
isolated perfused lung. 
 
Chemical  Concentration 
NaCl 120 mM 
KCl 4.3mM 
KH2PO3 1.1 mM 
NaHCO3 24 mM 
MgCl x 6H2O 1.3 mM 
CaCl2 2.4 mM  
Glucose 13.32 mM  
hydroxyethylamylopectin 
(mol wt 200,000) 
5% (wt/vol) 
 
 
2.3.3 Experimental protocols 
After termination of the initial steady-state period and performance of a control 
hydrostatic challenge, the lungs were exposed to ischemia by stopping the perfusion 
and switching the inhaled gas mixture to anoxic 5,3% CO2, 94,7% N2 (Messer, Siegen, 
Germany). For maintenance of positive intravascular pressure, the arterial and venous 
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catheters were clamped after adjustment of initial value of arterial pressure to 6 mm 
Hg. During ischemia, lungs were continuously ventilated with a warmed and 
humidified anoxic gas mixture. At the end of ischemia, ventilation was changed to 
normoxia, and perfusion was re-established by increasing the flow stepwise over 3 
min. Hydrostatic challenges were performed 30 and 60 after the onset of reperfusion. 
Duration of ischemic period and timings of hydrostatic challenges were designed 
based on previous studies performed in our laboratory (29, 55-57). 
Lungs were treated according to one of following protocols: 
1) I/R – lungs were exposed to ischemia with following reperfusion; no 
interventions were performed; 
2) NIC – nonischemic control, lungs were perfused and ventilated throughout 7 h; 
3) I/R + L-NMMA – unselective NOS inhibitor L-NMMA (400µM) was admixed 
to perfusion buffer 5 min before onset of ischemia; 
4) I/R + 1400W – selective iNOS inhibitor 1400W (10 µM) was applied into 
perfusion system 5 min before onset of ischemia; 
5) I/R + BYK 191023 – selective iNOS inhibitor (20 µM) was applied; 
6) I/R + VNIO – selective nNOS inhibitor VNIO (1µM) was applied into perfusion 
5 min before onset of ischemia; 
7) I/R + BAY 41-2272 – the substance (3µM) was admixed to perfusion buffer 5 
min before onset of ischemia. Dosage was chosen on the basis of our previous results 
as the most effective; 
8) I/R + apocynin – the substance in end concentration 0.5 mM was admixed to 
perfusion buffer 5 min before onset of ischemia; 
Criteria for termination of experiments were achieving 60 min after reperfusion or 
weight gain more than 25 g during reperfusion. 
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In separated set of experiments lungs were treated as described for NIC and I/R 
groups. After 10 min after onset of reperfusion experiment was stopped, lung tissue 
was snap frozen in liquid nitrogen and further used for western blotting. 
Measurements of ROS release in perfusate were performed in additional experiments 
with the same protocol. Additional control experiments with SOD 150 U/ml were 
performed. 
PMA stimulation experiments. Krebs-Henseleit buffer used for these experiments was 
incubated with 5 µM diethyldithiocarbamate overnight to allow sedimentation. Briefly 
before the experiments, 20 µM DFO and NaHCO3 were added. Lungs were prepared 
as described previously. After the initial steady state period CPH (1mM) was added to 
the circulating buffer fluid. Five minutes later, one of three different protocols was 
started: 
1) PMA - one hour perfusion period followed by a bolus application of PMA, end 
concentration 1µM, into the pulmonary artery. Every 5 min samples from the venous 
outflow of the isolated lung were taken in 50µl glass capillaries and measured by 
spectroscopy as described previously. After PMA stimulation measurements were 
performed every 2 min. 
2) BAY 41-2272 + PMA – after 30 min of perfusion with CPH 1mM the sGC 
activator was applied with following PMA simulation after next 30 min. 
Measurements were performed as described for the PMA group. 
3) SOD controls – after steady state period SOD 150/ml was admixed to the buffer, 
which was followed by CPH 1mM application. Subsequent interventions were 
executed as described for PMA and BAY 41-2272 + PMA groups. 
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Table 4. Devices and systems applied for the model of isolated perfused rabbit 
lung 
 
Device Supplier 
Pump  
Masterflex Easy-load 7518-10 
Masterflex, Gelsenkirchen, Germany 
Heater 
Thermomix BM 
B. Braun Biotech International, 
Melsungen, Germany 
Cooler 
Frigomix 
B. Braun Biotech International, 
Pfieffewiesen, Germany 
Ventilator 
6025 Cat/rabbit ventilator 
Hugo Sachs Elektronik, March, 
Germany 
Force Transducer 
Type U1A 
Hottinger Baldwin Messtechnik, 
Fuchstal, Germany 
Amplifier 
Transbridge 4M 
World Precision Instruments, Berlin, 
Germany 
Analog-to-digital converter 
PCLD-8115 wiring terminal board Rev. 
A2 
Advantech, Feldkirchen, Germany 
Flowmeter 
G10a6142fa2b1x0 with precision bore 
flowrator tube No. FP ¼-25-G-5/81 
Bailey Fischer Porter, Solingen, 
Germany 
Computer 
Unicorner 
Unicorner, Stuttgart, Germany 
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2.4 Isolated perfused mouse lung technique 
2.4.1 Setup of isolated perfused mouse lung 
The model of isolated perfused and ventilated mouse lung is depicted in the scheme 2. 
Devices and systems employed for the setup are listed in the table 5.  
 
Table 5. Devices and systems for the model of isolated perfused mouse lung 
 
Device Supplier 
Peristaltic pump REGLO Digital 
MS-4/12 
Ismatech SA, Labortechnik-Analytik, 
Glattbrugg, Switzerland 
Piston pump Minivent Type 845 Hugo Sachs Elektronik Harvard Apparatus, 
GmbH, March-Hugstetten, Germany 
Transbridge BM4 World Precision Instruments, Berlin, 
Germany 
Thermomix UB Braun Melsungen, Melsungen, Germany 
Frigomix1495 Braun Melsungen, Melsungen, Germany 
Research Grade Isometric Force 
Transducer 
Harvard Apparatus, Holliston, USA 
Blood analyser ABL 330 Radiometer, Copenhagen, Denmark 
Magnetic stirrer Ret-Basic IKA Labortechnik, Stauffen, Germany 
MiniScope MS100 Magnettech, Berlin-Adlershof, Germany 
 
 
MATERIALS AND METHODS  - 20 - 
 
2.4.2 Isolated mouse lungs preparation 
Mice were deeply anesthetized intraperitoneally with pentobarbital sodium (100mg/kg 
body weight) and anticoagulated with heparin (1000U/kg) by intravenous injection. 
Animals were then intubated via a tracheostoma and room air ventilated using a piston 
pump (Minivent Type 845, Hugo Sachs Elektronik, March-Hugstetten, Germany) with 
a tidal volume of 300µl, a frequency of 90 breaths/min and a positive end-expiratory 
pressure 3 cmH2O. Midsternal thoracotomy was followed by insertion of catheters into 
the pulmonary artery and left atrium. Using a peristaltic pump (REGLO Digital MS-
4/12, Ismatech SA, Labortechnik-Analytik, Glattbrugg, Switzerland), perfusion with 
sterile Krebs–Henseleit buffer (Serag-Wiessner, Naila, Germany), via the pulmonary 
artery was started at 4°C and a flow of 0.2 ml/min. In parallel with the onset of 
artificial perfusion, ventilation was changed from room air to a pre-mixed normoxic 
normocapnic gas with 21%O2, 5.3%CO2, balanced with N2 (Air Liquide, Deutschland 
GmbH, Ludwigshafen, Germany). The lungs were removed from the thorax without 
interruption of ventilation and perfusion and were freely suspended from a force 
transducer for the monitoring of organ weight in a temperature-equilibrated, 
humidified chamber at 37.5°C. After rinsing the lungs with ≥20 ml buffer, the 
perfusion circuit was closed for recirculation. Meanwhile, the flow was slowly 
increased from 0.2 to 2 ml/min (total system volume 15 ml). Left atrial pressure was 
set at 2.0 mmHg, and the whole perfusion system was equilibrated at 37.5°C. 
Pressures in pulmonary artery (Ppa) and left atrium were registered with pressure 
transducers via small diameter catheters and digitized with an analog-to-digital 
converter, thus allowing data sampling with a personal computer. The capillary 
filtration coefficient (Kfc) and total vascular compliance were determined 
gravimetrically from the slope of the lung weight gain curve induced by a 7.5-mmHg 
step elevation of the venous pressure for 8 min as previously described (54). Lung 
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weight gain was calculated as the difference in organ weight measured directly before 
and 5 min after each of these pressure elevation manoeuvres. Vascular compliance 
was calculated from the initial steep increase in lung weight on a step change in 
pressure. 
Inclusion criteria for the study were 1) a homogeneous white appearance of the lungs 
with no signs of edema, hemostasis, or atelectasis; 2) initial Ppa and ventilation 
pressure values in the normal range; and 3) constancy of organ weight during an initial 
steady-state period of at least 20 min. 
 
2.4.3 Experimental protocols. 
 After termination of the initial steady-state period and performance of a control 
hydrostatic challenge, the lungs were exposed to ischemia by stopping the perfusion. 
The arterial and venous catheters were both clamped for maintenance of a positive 
intravascular pressure, which was initially adjusted to 8 mmHg. During ischemia, the 
lungs were continuously ventilated with anoxic gas mixture (95% N2, 5% CO2). At the 
end of ischemia, ventilation was changed to normoxia, and perfusion was 
re-established by increasing the flow stepwise over 3 min. Hydrostatic challenges 
were performed 30, 60, and 90 min after the onset of reperfusion. 
Lungs from wild type and NOS2 knockout mice were treated according to one of the 
following protocols:  
1) I/R - the lungs were exposed to 90 min of ischemia with following reperfusion, 
no interventions were performed;  
2) I/R + L-NMMA – 5 min before onset of ischemia L-NMMA 400 µM was 
admixed to the perfusion buffer; 
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3) I/R + BYK-191023 - 20 µM of BYK-191023 were admixed to the perfusion 
buffer; 
4) I/R + VNIO - vinyl-L-NIO (VNIO) 1 µM was admixed to perfusion buffer. 
In a separate set of experiments lungs from WT and iNOS KO mice were subjected to 
120min continuous normoxic perfusion only or 30 min normoxic perfusion followed 
by 90 min anoxic ischemia. At the end of ischemia or respective normoxic perfusion 
period, one set of lungs was removed and snap frozen in liquid nitrogen for isolation 
of mRNA and protein. A second set was fixed for immunohistochemistry in a 3% 
paraformaldehyde solution and then paraffin embedded. 
Each group encompassed four to eight independent experiments. All experiments were 
terminated 90 min after onset of reperfusion or when lung weight gain exceeded 1 g 
during reperfusion. 
 
2.5 Measurement of cGMP 
cGMP was determined in samples of pulmonary venous effluent before ischemia as 
well as 3, 30 and 60 min after the onset of reperfusion. The perfusate aliquots were 
immediately frozen in liquid nitrogen and stored in -20 °C until measurement. 
Samples were analysed with a commercially available RIA (Beckman-Coulter, 
Hamburg, Germany). Briefly, assay based on the competition between succinylated 
cGMP of the sample and a 125I-labeled tracer for binding to polyclonal antibody 
coated onto tubes. Measurements were carried out in duplicate. Samples were treated 
with perchloric acid to inhibit PDE activity and extract the cyclic nucleotide. The 
extracts were then succinylated and assayed. Radiation was detected by gamma-
counter “Cobra Auto-gamma” (Packard, Zurich, Switzerland). 
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2.6 Measurement of exhaled NO 
Measurements were performed as described by Spriestersbach et al. (58).Aliquots of 
exhaled gas sampled from the open-end tube immediately at the ventilator exhaust 
valve were provided continuously for measurement by chemoluminescence technique 
to NO analysator “Sievers 280”. This device uses ozone to oxidize NO to an excited-
state NO2; light emission occurring on transition of excited-state NO2, to ground-state 
NO2 is quantified. Daily calibration was performed with certified gas of known 
concentration 100 parts per billion (ppb) (Messer Griesheim, Herborn, Germany). The 
detection limit of NO in gas was 1 ppb (vol/vol). 
 
2.7 Measurement of NO metabolites in perfusate 
NO metabolites (nitrite, nitrate, peroxynitrite) were determined in perfusate samples 
by NOA “Sievers 280” (Seeheim, Germany) according to manufacturer instructions. 
Perfusate probes were sampled from venous effluent before ischemia as well as 3, 30 
and 60 min after the onset of reperfusion and frozen immediately and stored under -20 
°C until measurement. NO reaction products in samples were reduced by vanadium 
chloride at 95 ºC. Resulting gaseous NO was provided to NO analysator, which was 
connected to computer for data transfer and analysis by “NoaWin 32” software 
(DeMeTec, Langgons, Germany). 
 
2.8 Measurement of intravascular ROS release by electron spin resonance (ESR) 
spectroscopy 
Electron spin resonance (or electron paramagnetic resonance; ESR) is based on 
absorption of microwave radiation stimulated by an electromagnetic field in molecules 
such as free radicals and transition metal ions with unpaired electrons (59). In our 
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laboratory we employ ESR spectroscopy advanced by spin trapping adapted for the 
model of isolated perfused lung (60). 
ROS were measured by ESR spectroscopy using the spin probe 1-hydroxy-3-carboxy-
2,2,5,5-tetramethylpyrrolidine (CPH, Alexis Corporation, San Diego, USA). The 
triple-line spectrum of CP radical, a product of the reaction between ROS and CPH, 
was detected by ESR spectroscopy, using a “MS 100 spectrometer” (Magnettech, 
Berlin, Germany) ESR measurements were performed in field scan with the following 
settings: microwave frequency 9.78 GHz, modulation frequency 100 kHz, modulation 
amplitude 2 G, microwave power 18 mW.  
Isolated rabbit and mouse lungs were perfused with Krebs–Henseleit buffer, pretreated 
for 4 h with 50 g/L Chelex 100, to minimize contamination with transition metals. 
 
2.8.1 ROS measurements in rabbit lungs 
Spin trap CPH 1 mM was applied into perfusate 5 min before reperfusion. Tubings 
were flushed with perfusate containing spin trap, so that with first portions of 
perfusate the spin trap reached the lung upon onset of reperfusion. Samples from the 
venous outflow of the isolated lung were taken immediately after start of reperfusion 
in 50µl glass capillaries and measured at room temperature. Samples were taken every 
15 seconds during 1st min and then every 30 seconds after reperfusion. To decrease 
autooxidation of CPH due to iron, present in perfusate, DTPA in end concentration 
0.1mM was applied before CPH. 
 
2.8.2 ROS measurements in mouse lungs 
Stock solutions of CPH (10 mM), dissolved in 0.9% NaCl containing 1 mM 
diethylenetriamine-pentaacetic acid (DTPA) and purged with argon, were prepared 
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daily and kept under argon on ice. DTPA was used to decrease autooxidation of CPH 
catalyzed by trace amount of transition metals. 
Lungs from WT and NOS2 KO mice were exposed to anoxic ischemia for 90 min. 
The spin probe CPH (0.5 mM) was given into perfusate 5 min before onset of 
reperfusion. Samples from the venous outflow of the isolated lung were taken in 50 µl 
glass capillary tubes and measured immediately at room temperature. The samples 
were taken every 15 seconds during the first 3 minutes of reperfusion, and then every 
minute or 5 minutes, as appropriate. Experiments were also carried out in time-
matched nonischemic control lungs. 
The quantity of trapped ROS was directly calculated from the ESR spectrum of the 
probe, while the contribution of superoxide radical to the formation of CP was 
determined in parallel experiments performed in the presence of SOD in the buffer 
fluid (150 U/ml). 
 
2.9 Western blot assay 
The lungs were removed and immediately frozen in liquid nitrogen. They were then 
homogenised in lysis buffer containing 50 mM tris-(hydroxymethyl)-aminomethane 
(Tris)/HCl (pH 7.6), 150 mM NaCl, 10 mM CaCl2, 60 mM NaN3, 0.1% wt/vol Triton 
X-100 and a cocktail of protease inhibitors (Complete™ Protease Inhibitor Cocktail 
Tablets; Boehringer, Ingelheim, Germany) using a tissue homogenizer. Homogenates 
were centrifuged at 13,000 rpm at 4°C for 30 minutes. The supernatants were 
measured for protein content using Dye Reagent Concentrate (Bio-Rad Laboratories, 
Munich, Germany). Extracts containing equal amounts of protein (100 µg) were 
denatured by boiling for 10 minutes in Laemmli’s buffer containing β-
mercaptoethanol and separated on 7.5% SDS-polyacrylamide gels at 120 V. The 
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separated proteins were transferred to nitrocellulose membranes with a semidry 
transfer unit at 130mA for 2 hours. The blots were blocked and developed with: 
Mouse lung tissue - specific rabbit polyclonal Ig G antibodies: eNOS (BD 
Biosciences, Lexington, KY, USA, 1:1000), iNOS (Santa Cruz, Heidelberg, Germany, 
1:1000) and bNOS (Abcam, Cambridge, UK, 1:1000) and goat anti-rabbit HRP-
labelled secondary antibody (Promega, Germany, 1:30000). 
The bands were visualized using an enhanced chemiluminescence ECL Plus Western 
blotting detection reagents (Amersham Biosciences, Freiburg, Germany) and 
quantified by densitometry (Biometra, Germany). Density values are expressed 
relative to the β-actin (Abcam, Cambridge, UK) level in rabbit lung tissues and to the 
GAPDH (Abcam Ltd, Cambridge, UK) control level in mouse lung tissues of each 
sample. All densities reported are means and SEM of four separate experiments. 
 
 
Table 6. Reagents used for western blot assay. 
 
 
Reagent Company Catalogue number 
Tris base Sigma-Aldrich-
Aldrich- 
T1503 
Tween Sigma-Aldrich P7949 
Glycine Sigma-Aldrich G7126 
SDS Serva 20763 
Glycerol Sigma-Aldrich G5150 
Bromophenol blue   
Methanol Fluka 65545 
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Skimmed milk powder Roth T145.2 
Temed Sigma-Aldrich T-9281 
Acrylamide Fluka 0199 
Ammonium per sulphate Sigma-Aldrich A-3678 
Bis-acrylamide Sigma-Aldrich M-2022 
Tris HCl Sigma-Aldrich T-2788 
   
Reagent Company Catalogue number 
Triton x-100 Sigma-Aldrich T-8787 
Full range Rainbow ™ 
recombinant molecular weight 
marker  
Amersham RPN800V 
ECL plus western blotting 
detection system 
Amersham RPN2132 
Gel blotting paper 580x580 mm Schleicher & 
Schuell 
G8005 Ref. 
N:10426994 
Hyperfilm 18x24 cm (5-75 sheet 
bones) 
Amersham RPN175K 
eNOS/type II pab BD Transduction 
Labs 
610298 
Mouse monoclonal (6c5) to 
GAPDH-loading control 
Abcam Ab8245-10 
NOS2 (N-20) Santa Cruz Sc-51 
Rabbit polyclonal antibodies to 
bNOS 
Abcam Ab3511-100 
Anti-iNOS polyclonal antibodies BD Transduction 610332 
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labs 
Histostain (R)SP rabbit primary 
(AEC) 
Zymed Labs 95-6143 
Rabbit serum Zymed Labs 50-061 
Biotin-conjugated anti-rabbit  
goat Ig G 
Zymed Labs 50-232 
 
2.10 Immunohistochemical staining 
Paraffin-embedded lung tissue sectioned at a 2 µm thickness was deparaffinized in 
xylene and rehydrated in a graded ethanol series to phosphate-buffered saline (PBS, 
pH 7.2). Antigen retrieval was performed by pressure cooking in citrate buffer (pH 
6.0) for 15 min. Immunohistochemical staining was performed using anti-iNOS 
antibody (Santa Cruz Biotechnology, Santa Cruz, California, USA) in conjunction 
with an avidin-biotin-peroxidase kit as per manufacturer’s instructions (Zymed 
Laboratories, Burlingame, CA, USA). Briefly, the sections were pre-treated with 3% 
hydrogen peroxide to quench endogenous peroxidase activity. Then, the sections were 
incubated for 1h in 10% normal goat serum to block nonspecific binding sites prior to 
the application of primary antibodies. Sections were then incubated overnight at 4°C 
with the primary monoclonal antibody (1:100). Biotinylated anti rabbit 
immunoglobulin (Ig G) and then avidin-biotinylated enzyme complex were applied 
according to the manufacturer's instructions. After each incubation step, sections were 
washed briefly in PBS. Development of the dye was carried out with AEC substrate 
for 10 min. Finally, sections were counterstained with hematoxylin and coverslipped 
using mounting medium. 
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2.11 RT-PCR  
Total RNA was isolated from frozen lungs using TRIzol Reagent according to the 
manufacturer’s instructions (Invitrogen, Carlsbad, CA, USA). One microgram of RNA 
from each sample was reverse transcribed to cDNA with Improm-II Reverse 
Transcription System (Promega, Madison, WI, USA). Three microliters of this RT 
reaction were added to each 50 µl semi quantitative PCR reaction. Oligonucleotide 
primers used to amplify eNOS were (forward) 5'-AAGACAAGGCAGCGGTGGAA-
3' and (reverse) 5'-GCAGGG GACAGGAAATAGTT-3', for nNOS were (forward) 5'-
AATGGAGACCCCCAG AGAAT-3' and (reverse) 5'-
TCCAGGAGAGTGTCCACTGC-3', for iNOS were (forward) 5'-
ACGCTTGGGTTTGTTCACT-3' and (reverse) 5'-GTCTCTGGGTCC TCTGGTCA-
3', for GAPDH were (forward) 5'-GTGATGGGTGTGAACCACGAG-3' and (reverse) 
5'-CCACGATGCAAGTTGTCA-3'. PCR products were analysed by 1.5% (w/v) 
agarose gel electrophoresis. The expected sizes of PCR products were 292, 281, 468 
and 179 bp for eNOS, nNOS, iNOS and GAPDH respectively. Identity of the product 
was confirmed with sequence analysis. 
 
2.12 Data analysis 
Data are expressed as means ± s.e.m. Differences between two groups were evaluated 
by t-test. For multiple comparisons one-way analysis of variance followed by a post 
hoc Student-Newman-Keuls test was used. P values< 0.05 were considered to 
represent a significant difference. Analysis was performed using SPSS statistic 
software package.  
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3 RESULTS 
 
3.1 Role of different NO synthases in I/R injury 
3.1.1 Isolated perfused rabbit lungs 
Permeability and LWG 
In rabbit lungs in preischemic period low Kfc values indicated intact endothelial 
barrier properties similarly in all experimental groups. Four hours of ischemic 
exposition induced dramatically elevated Kfc values on reperfusion with subsequent 
severe edema formation in control lungs (Fig. 1). Unspecific NO synthase inhibition 
prevented I/R induced lung injury. Specific iNOS or nNOS inhibition protected 
against I/R induced permeability and weight gain increase. 
Ppa 
 No significant differences in Ppa between groups were observed. After reperfusion in 
I/R group a transient Ppa increase was detected (16.3 ± 2.1 mm Hg) with following 
decrease until baseline level (Fig. 6). Nonspecific NO synthase or specific iNOS or 
nNOS inhibition did not significantly influence this Ppa increase. 
Nitric oxide 
NO release detected in exhaled gas (NOex) mixture was 75.3±5.5 ppb under pre-
ischemic control conditions in the rabbit lungs. Upon starting ischemia NOex 
decreased immediately and remained low during whole ischemic period (1.3 ± 1.1 ppb 
shortly before reperfusion). After onset of reperfusion levels of NOex returned to 
baseline levels (Fig. 5). NO metabolites in perfusate accumulated continuously (Fig. 
5C). L-NMMA inhibited NO production completely, which was confirmed by rapid 
drop of NOex and diminished accumulation of NO metabolites after inhibitor 
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application. Moreover, L-NMMA blocked the recovery of NO production after 
reperfusion (23.8 ± 1.9ppb, p<0.001 vs. I/R). Specific iNOS or nNOS inhibition did 
influence neither NOex nor NO metabolites accumulation in recirculating buffer.  
Intravascular ROS release 
In the rabbit lungs exposed to ischemia an increase in ROS release in perfusate upon 
onset of reperfusion was detected, whereas in nonischemic control lungs no significant 
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Fig. 1. Impact of NO synthase 
inhibition on capillary filtration 
coefficient (Kfc) and lung 
weight gain (LWG) in isolated 
perfused rabbit lung. I/R lungs 
underwent 4 hour ischemia with 
following reperfusion, no 
treatment was administered. 
Time matched nonischemic 
control (NIC) lungs were 
perfused and normoxically 
ventilated throughout 6 hrs. 
NOS inhibitors L-NMMA 400 
µM, 1400W 10 µM, BYK 
191023 20 µM, or VNIO 1 µM 
were applied 5 min before 
ischemia according to protocol. 
Kfc was determined 
gravimetrically from the slope 
of the lung weight gain curve 
induced by a 7.5-mmHg step 
elevation of the venous pressure 
for 8 min. LWG was calculated 
as the difference in organ weight 
measured directly before and 5 
min after each of these pressure 
elevation maneuvers.  
 
A. Thirty min after onset of reperfusion all treatment groups demonstrated significant reduction of elevated 
Kfc (p<0.05 vs. I/R). B. Thirty min after reperfusion all treatment groups showed significant reduction of 
elevated LWG (p<0.05 vs. I/R). Data presented as mean ± SEM. 
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increase was observed (Fig. 11). Application of superoxide dismutase (SOD) reduced 
significantly CP- signal suggesting that the superoxide is the main radical produced. 
NOS inhibition by L-NMMA diminished ROS release. Both iNOS and nNOS 
inhibition reduced ROS release in perfusate.  
 
3.1.2 Wild type mouse lungs 
Permeability and LWG 
Mouse lungs in preischemic period demonstrated low Kfc values indicating intact 
endothelial barrier properties in all experimental groups. Ninety min of ischemic 
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Fig. 2. Impact of NO synthase inhibition 
on capillary filtration coefficient (Kfc) 
and lung weight gain (LWG) of isolated 
perfused wild type mouse lungs. Lungs 
from wild type mice were exposed to 
ischemia with anoxic ventilation for 90 
min with following reperfusion. Time 
matched nonischemic control lungs 
underwent 180 min perfusion with 
normoxic ventilation. When indicated, 
LNMMA 400 µM, 1400W 10 µM, 
BYK-191023 20 µM, or VNIO 1 µM 
was admixed into the buffer solution 5 
min before the onset of anoxic ischemia. 
Data presented as mean ± SEM. A. 
Thirty min after onset of reperfusion all 
treatment groups demonstrated 
significant reduction of elevated Kfc 
(p<0.05 vs. I/R). B. Thirty min after 
reperfusion all treatment groups showed 
significant reduction of elevated LWG 
(p<0.05 vs. I/R). Data presented as 
mean ± SEM. 
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exposition induced dramatically elevated Kfc values on reperfusion with subsequent 
edema formation in control lungs (Fig. 2). Unspecific NO synthase inhibition 
prevented permeability disturbances and lung weight gain. Either specific iNOS or 
nNOS inhibition protected against I/R induced lung injury. 
 
Ppa 
At the baseline in all treatment groups similar values of Ppa were measured (8.1 ± 0.6 
mm Hg in WT I/R group). Reperfusion induced transient Ppa increase, which was not 
influenced by NO synthase inhibitors (Fig. 6A). 
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Fig. 3. Impact of NO synthase inhibition 
on capillary filtration coefficient (Kfc) 
and lung weight gain (LWG) of isolated 
perfused iNOS deficient mouse lungs. 
Lungs were exposed to ischemia with 
anoxic ventilation for 90 min. When 
indicated, L-NMMA 400 µM, BYK 
191023 20 μM, or VNIO 1 µM was 
applied into the buffer solution 5 min 
before the onset of anoxic ischemia. 
Data presented as mean ± SEM. A. 
Thirty min after onset of reperfusion L-
NMMA and VNIO treatment groups 
demonstrated significant reduction of 
elevated Kfc (p<0.05 vs. I/R). B. Thirty 
min after reperfusion L-NMMA and 
VNIO treatment group showed 
significant reduction of elevated LWG 
(p<0.05 vs. I/R). Data presented as 
mean ± SEM. 
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NO synthase expression 
In the WT mouse lungs subjected to ischemia with anoxic ventilation eNOS protein 
and mRNA levels were significantly reduced, while nNOS expression was moderately 
increased (Figs. 8 and 9). . In the WT mouse lungs subjected to ischemia with anoxic 
ventilation upregulation of iNOS mRNA was observed (Fig. 8). iNOS protein 
upregulation was noted after anoxic ischemia by immunohistochemistry. iNOS was 
found mainly localized in the airway epithelium as well as in smaller vessels (Fig. 10).  
Intravascular ROS release 
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Fig. 4. Impact of NO synthase inhibition 
on capillary filtration coefficient (Kfc) 
and lung weight gain (LWG) of isolated 
perfused eNOS deficient mouse lungs. 
Lungs were exposed to ischemia with 
anoxic ventilation for 90 min. When 
indicated, LNMMA 400 µM, 1400W 10 
μM, or VNIO 1 µM was admixed with 
the buffer solution 5 min before the 
onset of anoxic ischemia. Data 
presented as mean ± SEM. A. Sixty min 
after onset of reperfusion VNIO 
treatment group demonstrated 
significant reduction of elevated Kfc 
(p<0.05 vs. I/R). B. Sixty min after 
reperfusion VNIO treatment group 
showed significant reduction of elevated 
LWG (p<0.05 vs. I/R). Data presented 
as mean ± SEM. 
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In the WT mouse lungs exposed to ischemia an increase in ROS release in perfusate 
upon onset of reperfusion was detected (Fig. 11). Application of superoxide dismutase 
(SOD) reduced significantly CP- signal suggesting that the superoxide is the main 
radical produced. NOS inhibition by L-NMMA diminished ROS release. Both iNOS 
and nNOS inhibition reduced ROS release in perfusate.  
 
3.1.3 iNOS KO mouse lungs 
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Fig. 5. Impact of NOS synthase inhibition on NO in 
exhaled gas and in circulating buffer in rabbit lungs 
undergoing ischemia/reperfusion. A. NO was 
continuously monitored in the exhaled gas mixture. 
Lungs were exposed to ischemia with anoxic 
ventilation for 4 hours. L-NMMA abrogated NO 
exhalation and blocked restoration of NOex after 
reperfusion (p<0,001 vs. I/R). B. Detailed 
information about NOex for indicated timepoints. C. 
Concentration of NO metabolites was measured in 
perfusate samples in preischemia, after onset of 
reperfusion and then every 30 min. Values are given 
as mean + SEM 
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 In preischemic iNOS KO mouse lungs demonstrated permeability not differing from 
that of their wild type counterparts. Interestingly, iNOS KO mouse lungs were not 
protected against I/R injury (Fig. 3). After exposure to ischemia and reperfusion they 
developed injury to the same degree as WT louse lungs did. However, when non-
selective NOS inhibitor L-NMMA was administered before the ischemic period, both 
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Fig. 6. Effect of NO synthase inhibition on reperfusion induced increase in pulmonary arterial pressure. 
Baseline Ppa represents pressure after steady state period. Reperfusion rise demonstrates Ppa on 5th min of 
reperfusion, when perfusion was completely re-established. A. Ppa values at baseline and after reperfusion 
for rabbit lungs are presented. Reperfusion induced dramatic Ppa increase after reperfusion (p<0.05 vs. 
NIC). B. Ppa values at baseline and after reperfusion of isolated perfused WT mouse lungs. C. Ppa values 
at baseline and after reperfusion of isolated perfused iNOS KO mouse lungs are presented. D. Ppa values at 
baseline and after reperfusion of isolated perfused eNOS KO mouse lungs are presented. 
Data presented as mean ± SEM 
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the dramatic rise in Kfc and the severe edema formation were significantly attenuated, 
with values approaching those in WT mouse lungs pre-treated with L-NMMA. 
Specific nNOS inhibition prevented I/R induced permeability increase and fluid 
retention in lungs. Specific iNOS inhibition, as expected, did not demonstrate any 
effect. 
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Fig. 7. Baseline expression of eNOS and nNOS in lung homogenates from wild type an iNOS-KO mice. 
Western blot analysis was performed by immunodetection with antibodies against eNOS and nNOS. A. The 
specific antibodies recognize protein at a molecular mass 140 kDa and 155 kDa respectively. 
B. Quantification of the NOS signal. Values are expressed as ratio of obtained signal to GAPDH expression. 
iNOS KO mouse lungs demonstrate higher nNOS expression at baseline. *** p<0.001 vs WT mouse lungs. 
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Ppa 
At baseline iNOS KO mouse lungs demonstrated Ppa (8.4 ± 0.1 mm Hg) not differing 
from that of WT mouse lungs. Extent of Ppa increase after reperfusion was similar 
between WT and iNOS KO mouse lungs and was not changed by NO synthase 
inhibitors (Fig. 6C). 
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Fig. 9. Changes in the expression of NOS isoforms in lungs from WT (A) and iNOS KO (C) mice after 
exposure to anoxic ischemia. Mouse lungs were subjected to 120 min continuous normoxic perfusion 
(normoxia) or 30 min normoxic perfusion followed by 90 min anoxic ischemia (ischemia). Western blot 
analysis was performed from proteins obtained from the lungs. B. and D. The bar graphs illustrate 
quantification of eNOS or nNOS expression levels normalized to GAPDH levels. Data presented as means 
± SEM. * p < 0.05 vs. respective normoxia group. 
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NO synthase expression 
At baseline in the iNOS KO mouse lungs when compared with WT mouse lungs 
decreased levels of eNOS and increased levels of nNOS expression were observed 
(Fig. 7). In that mouse lungs, ischemia with anoxic ventilation induced further 
decrease of eNOS protein and mRNA level as well as the decreased amount of nNOS 
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Fig. 8. Effects of anoxic ischemia on expression of NOS 
isoforms in mouse lung. Lungs from WT and iNOS KO mice 
were subjected to 120 min cotinous normoxic perfusion 
(normoxia) or 30 min normoxic perfusion followed by 90 min 
anoxic ischemia (ischemia). Isoform-specific NOS transcripts 
were detected by RT-PCR in RNA extracted from these lungs. A. Electrophoregram of PCR products is 
demonstrated. The bar graphs illustrate quantification of (B) eNOS, (C) nNOS, (D) iNOS expression levels 
normalized to GAPDH levels. Data presented as mean ± SEM. * p < 0.05, *** p < 0.001 compared to 
respective normoxia group. 
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protein and mRNA. As expected, no iNOS expression was detected at baseline and 
after I/R (Figs. 8, 9). 
Intravascular ROS release 
After onset of reperfusion iNOS KO mouse lungs demonstrated increased ROS release 
into recirculating buffer. In presence of SOD the increase was considerably reduced 
confirming that signal derives mainly from superoxide radical. Both, nonspecific NOS 
and specific nNOS inhibition reduced the increase, whereas selective iNOS inhibition 
did not demonstrate any effect (Fig. 12). 
 
 
 
Fig. 10. Immunohistochemical staining 
for iNOS in mouse lungs after 
exposure to anoxic ischemia. Lungs 
from WT (A and B) and iNOS KO (C 
and D) mice were subjected to 120 min 
continuous normoxic perfusion  (A and 
C) or 30 min normoxic perfusion 
followed by 90 min anoxic ischemia (B 
and D). Brownish staining indicates 
positively stained cells (arrows). 
Anoxic ischemia up-regulated iNOS 
expression in WT mouse lungs. In 
iNOS KO mouse lungs no iNOS 
protein was detected (C and D). 
Representative results from 3 separate 
experiments are documented. No 
staining was detected when the primary 
antibody was omitted from the protocol 
(data not shown). 
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3.1.4 eNOS KO mouse lungs 
 
Permeability and LWG 
Lungs from eNOS KO mouse subjected to I/R developed injury to the same extent as 
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Fig. 11. Influence of NOS inhibition on ROS release in perfusate after reperfusion in the lungs of rabbits, wild type, 
iNOS KO, and eNOS KO mice. The rabbit lungs underwent 4 h ischemia with following reperfusion. When indicated 
NO synthase inhibitors were applied 5 min before onset of ischemia. After reperfusion several samples from venous 
effluent were collected and measured by ESR immediately. From obtained signal curve regression coefficient was 
calculated. In time matched nonischemic control rabbit lungs spin probe was applied correspondingly at 300th min 
during perfusion. The mouse lungs were subjected to the 90 min of anoxic ischemia with following reperfusion. 
When indicated, NO synthase inhibitors were applied 5 min before onset of ischemia. Spin trap CPH 1 mM was 
applied into perfusate shortly before reperfusion. After starting reperfusion several samples of venous effluent were 
collected and serial measurements were performed immediately. From obtained signal curve ratio of signal increase 
was calculated. A. Rabbit lungs. NO synthase inhibition reduced intravascular ROS release (p<0.05 vs I/R). B. Wild 
type mouse lungs. NO synthase inhibition reduced ROS release into recirculating buffer (p<0.05 vs I/R). C. iNOS 
deficient mouse lungs. Treatment with L-NMMA or VNIO reduced ROS release (p<0.05). D. eNOS deficient mouse 
lungs. NO synthase inhibition reduced intravascular ROS release (p<0.05 vs I/R). Data presented as mean ± SEM. 
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the lungs from WT mouse did (Fig. 4). Neither nonspecific NOS inhibition nor 
specific iNOS inhibition prevented tissue damage. Pre-treatment with nNOS inhibitor 
VNIO protected against I/R induced Kfc and LWG increase. 
 
Ppa 
eNOS KO mouse lungs demonstrated higher Ppa (8.7±0.3 mm Hg, p< 0.01 vs. WT) at 
baseline. Reperfusion induced Ppa increase was similar between WT and eNOS KO 
mouse lungs. Administration of NO synthase inhibitors did not reduce Ppa increase 
(Fig. 6D). 
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Fig. 12. Impact of sGC stimulation and 
NADPH oxidase inhibition on capillary 
filtration coefficient (Kfc) and lung 
weight gain (LWG) in isolated perfused 
rabbit lung. sGC stimulator BAY 
412272 3µM or NADPH oxidase 
inhibitor apocynin 0.5 mM were applied 
5 min before ischemia. Kfc was 
determined gravimetrically from the 
slope of the lung weight gain curve 
induced by a 7.5-mmHg step elevation 
of the venous pressure for 8 min. LWG 
was calculated as the difference in organ 
weight measured directly before and 5 
min after each of these pressure 
elevation maneuvers. A. Thirty min 
after onset of reperfusion all treatment 
groups demonstrated significant 
reduction of elevated Kfc (p<0.05 vs. 
I/R). B. Thirty min after reperfusion all 
treatment groups showed significant 
reduction of elevated LWG (p<0.05 vs. 
I/R). Data presented as mean ± SEM. 
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Intravascular ROS release  
Reperfusion induced ROS release from eNOS KO mouse lungs was inhibited by L-
NMMA, specific iNOS, and nNOS inhibitors (Fig. 11D). 
 
3.2 Role of sGC in I/R injury 
 
BAY 41-2272 application led to significant increase in cGMP concentration in 
perfusate (Fig. 14). NOex levels were not influenced by administration of the 
substance (Fig.15). No significant changes in basal Ppa after BAY 41-2272 treatment 
were observed. However, in these lungs less pronounced Ppa increase after 
reperfusion was detected (9.9 ± 0.6 mm Hg, p<0.05 vs. I/R) (Fig. 13). sGC stimulation 
significantly attenuated vascular leakage and reduced edema formation (Kfc 4.4E-04 ± 
0.5E-04 cm3 x s-1 x mmHg x g, p<0.01). Changes in weight gain correlated well with 
that of Kfc values (Fig. 12). These observations were paralleled by reduced ROS 
release into perfusate in the lungs pre-treated with BAY 41-2272 (Fig. 16). 
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Fig. 13. Effect of sGC stimulation and 
NADPH oxidase inhibition on 
reperfusion induced increase in 
pulmonary arterial pressure. Baseline 
Ppa represents pressure after steady state 
period. Reperfusion demonstrates Ppa on 
5th min of reperfusion, when perfusion 
was completely re-established. 
Reperfusion induced dramatic Ppa 
increase after reperfusion (p<0.05 vs. 
NIC). BAY 41-2272 reduced extent of 
the Ppa increase (p<0.05 vs. I/R). 
Data presented as mean ± SEM 
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Fig. 14. Effect of sGC stimulation 
on cGMP release in buffer.  
cGMP was measured in 
recirculating buffer using RIA. 
Buffer samples were collected 
during preischemia, after onset of 
reperfusion and then 30 min. BAY 
412272 increased the concentration 
of cGMP. (***p<0.001 vs. I/R). 
Data presented as mean ± SEM. 
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Fig. 15. Impact of BAY 412272 or apocynin application on NO in exhaled gas in rabbit lungs undergoing 
ischemia/reperfusion. NO was continuously monitored in the exhaled gas mixture. Lungs were exposed to 
ischemia with anoxic ventilation for 4 hours with following reperfusion. BAY 412272 or apocynin were 
administered 5 min before onset of ischemia. Values are given as mean + SEM 
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3.3 Role of NADPH oxidases in I/R 
Application of the NADPH oxidase inhibitor apocynin protected against I/R induced 
injury (Fig. 13). This substance protected against increase in permeability and reduced 
weight gain (14.4±2.34 g, p<0.05 vs. I/R). Apocynin did not influence NOex levels 
(Fig. 15). Inhibition of NADPH oxidases was confirmed by detection of reduced ROS 
release in the perfusate in apocynin treated lungs (Fig. 16). 
 
3.4 Interaction between NO-cGMP pathway and NADPH oxidase 
Treatment with PMA, the NADPH oxidase stimulator, resulted in increased 
intravascular ROS release in isolated lungs, which was accompanied by pronounced 
increase in Ppa (Fig. 17). BAY 41-2272 inhibited significantly both the increased ROS 
production (Fig. 17A) and Ppa elevation (Fig. 17B). SOD completely suppressed 
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Fig 16. Impact of BAY 412272 and apocynin on ROS release into perfusate. BAY 412272 3 µM or 
apocynin 0.5 µM were applied in pre-ischemia. Spin trap CPH 1 mM was applied into perfusate 5 min 
before reperfusion. Aliquots of perfusate were taken from lung effluent and measured by ESR spectroscopy 
immediately. From serial measurements curves of ROS accumulation in buffer were obtained. Regression 
coefficients of the slope of curve were calculated. Both BAY 42272 and apocynin demonstrated significant 
inhibition of ROS release into perfusate (p<0.05 vs I/R). Data presented as mean ± SEM 
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superoxide release accompanied by a reduced pressure response. 
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Fig 17. Influence of BAY 412272 on PMA stimulated ROS production and Ppa increase. Lungs were 
stimulated with PMA 1 µM either in presence or in absence of BAY 412272. Control measurements were 
performed in presence of SOD 150 U/ml throughout the experiments. A. changes in the increase rate of the 
ESR signal intensity (fold increase) by comparison of values prior to and after 30 min of PMA stimulation 
are presented; B. values of Ppa 30 min after PMA stimulation are shown. * p< 0.05 vs. PMA group. Data 
presented as mean ± SEM 
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4 DISCUSSION 
 
Despite an intensive research, the pathomechanisms of I/R induced lung injury remain 
unclear. The aim of our investigation was to evaluate the role of NO synthases in 
mediation of I/R injury and the role of NO-cGMP signalling pathway in regulation of 
NADPH oxidase activity during the course of I/R.  
 
4.1 The Main findings of this study were following:  
 iNOS and nNOS contribute to I/R induced lung injury via ROS production 
 there is a complex interaction between NO synthase isoforms 
 direct sGC stimulation protects against I/R injury via interaction with activation of 
NADPH oxidases  
I/R induced lung injury is characterized by an increased vascular permeability, which 
leads to fluid accumulation in pulmonary interstitium and edema formation. 
Previously, it has been demonstrated that the reperfusion induced transient pressure 
elevation is not the driving force for subsequent capillary leakage (7). Indeed, similar 
observations have been made in our study. NO synthase inhibitors prevented I/R 
induced lung injury without influencing reperfusion induced Ppa increase.  
 
4.2 Role of NO synthase isoforms in I/R injury 
In our study, complex changes in expression of NOS isoforms in the course of I/R 
were observed. Ischemia induced the upregulation of iNOS on the mRNA transcript 
and protein level in wild type mice. By immunohistochemical staining, localization of 
the upregulated iNOS was found in small vessels, suggesting the possible involvement 
of the enzyme in mediation of I/R induced vascular disturbances. In addition, the 
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downregulation of eNOS and moderate upregulation of nNOS were observed. These 
findings are in line with other reports (4), where upregulation of iNOS and 
downregulation of eNOS in the model of rat lung transplantation was observed.  
To reveal the contribution of each isoform to I/R injury, NO synthase inhibitors were 
applied. Unspecific NOS inhibition protected against damage in rabbits and wild type 
mice, confirming involvement of NO synthases in mediation of I/R injury. Complete 
NOS inhibition was confirmed by abrogation of NO exhalation after L-NMMA 
application. Specific iNOS as well as nNOS inhibition prevented I/R induced 
permeability increase and fluid retention in the lung, suggesting that both isoforms 
contribute to the tissue damage. Specific iNOS and nNOS inhibition was confirmed by 
monitoring of NO exhalation. After application of either 1400W or BYK 191023, or 
VNIO in rabbit lungs no change in the exhaled nitric oxide was observed. Indeed, it 
has been demonstrated that exhaled NO is derived from eNOS in the setup of isolated 
perfused rabbit lung (61). These results are in line with the findings of other authors 
(17), who demonstrated the an upregulation of iNOS in the course of I/R and 
protective effects of its inhibition. 
Interestingly, iNOS KO mice in our study were not protected against I/R injury. In the 
course of I/R, they demonstrated disturbed permeability and fluid retention 
comparable with that of wild type animals. Furthermore, iNOS KO mice demonstrated 
a different pattern of NOS isoform expression at baseline. They had lower eNOS and 
higher nNOS expression comparing to wild type mice. Ischemia induced further 
reduction in eNOS expression and downregulation of nNOS. As expected, no 
expression of iNOS was observed. In these animals unspecific NOS inhibition 
prevented I/R induced permeability disturbances and lung weight gain. Specific iNOS 
inhibition did not demonstrate protective efficacy. Selective nNOS inhibition 
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prevented lung injury, suggesting that nNOS mediates I/R lung injury in the iNOS KO 
animals.  
To determine the contribution of eNOS in development of I/R injury, we employed 
eNOS KO mice. These animals phenotypically were not different from their WT 
counterparts. However, the isolated lungs demonstrated higher Ppa at baseline. Lungs 
from eNOS KO mice subjected to I/R demonstrated increased permeability and lung 
weight gain. Interestingly, total NOS inhibition in these lungs was not able to protect 
from injury. Additionally, selective iNOS inhibition did not show any protective 
effect. Selective nNOS inhibition prevented I/R induced lung injury. These findings 
may suggest that in these animals, as an adaptation to the absence of crucial eNOS 
gene, iNOS takes over the function of eNOS and exerts protective role. Hence, 
complex changes in expression and function of genes may take place in these 
genetically modified mice. 
Furthermore, an increase in the nNOS expression in mouse lungs in the course of I/R 
was observed. Inhibition of this enzyme reduced intravascular ROS release and 
protected against I/R injury. Additionally, in iNOS KO and eNOS KO mouse lungs 
nNOS inhibition prevented permeability disturbances and weight gain. Similarly, 
nNOS has been found to be involved in mediation of acute lung injury induced by 
smoke inhalation and bacterial insufflations (62) and its inhibition improved gas 
exchange, reduced wet to dry ratio, and decreased plasma nitrate level. 
Thus, we conclude that NO synthases contribute to I/R induced lung injury and their 
inhibition prevents tissue damage. The mechanisms of their detrimental effect are not 
completely clear. NO synthases could contribute to I/R injury by production of ROS 
by at least two mechanisms: 1) peroxynitrite formation from NO in the oxidative 
environment, where superoxide is derived from other enzymes, e.g. NADPH oxidases 
and 2) uncoupling of NOS and direct superoxide production by uncoupled enzyme. 
DISCUSSION  - 50 - 
 
Indeed, in rabbits and wild type mice increased ROS release into recirculating buffer 
after reperfusion was observed. This increase was inhibited by L-NMMA, suggesting 
that NO synthases are the source of ROS. Specific iNOS and nNOS inhibitors 
demonstrated similar efficacy. Lungs from both iNOS and eNOS KO mice 
demonstrated increased intravascular ROS release after reperfusion. In iNOS KO 
mouse lungs, nonselective NOS and selective nNOS inhibition prevented this increase, 
suggesting that nNOS is the source of reactive oxygen species. In eNOS KO mouse 
lungs selective iNOS or nNOS inhibition led to reduced ROS release. Hence, NO 
synthases contribute to the development of I/R injury by ROS production.  
Thus, our results with pharmacological inhibitors suggest that iNOS and nNOS 
contribute to I/R induced lung injury. Results obtained from iNOS KO mouse lungs 
confirm these findings. However, results from eNOS KO mice are difficult to interpret 
because of complex compensatory changes in expression and function of NOS 
synthase isoforms. 
This is not the first study where the results derived from genetically modified animals 
do not correlate with the results obtained from studies with pharmacologic enzyme 
inhibition. For instance, Zeidler et al. (63) demonstrated that iNOS KO mice 
challenged with LPS and interferon gamma developed inflammatory reaction, which 
was not different to that of wild type animals. In the light of other studies (64) where 
anti-inflammatory effect of iNOS inhibition was observed, this is an unexpected 
result. Instead, resistance of iNOS KO mice against LPS induced injury would be 
expected. Since NO synthases are crucial genes involved in control of vascular 
homeostasis, angiogenesis and immunity, deletion of one isoforms should lead to 
compensatory changes in expression and function of remaining isoforms. In the study 
of Zeidler et al., the function of nNOS and eNOS has not been elucidated. In contrast, 
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pharmacological inhibitors were applied to KO mice in our study to elucidate the 
functions of other expressed NO synthase isoforms. 
These experiments revealed transformed function of expressed NOS isoforms in KO 
mice. In iNOS KO mice, nNOS seems to take over the function of absent iNOS, thus 
counteracting the potential protective effect of iNOS deletion. In eNOS KO mice, 
iNOS seems to take over the function of deleted eNOS, thus partly exerting protective 
effect. 
 
4.3 sGC stimulation in I/R injury 
The next question was to study the role of soluble guanylyl cyclase in mediation of I/R 
injury. But pharmacologic stimulation or genetic over-expression of eNOS would 
enhance NO production and could contribute to oxidative stress, as it has been 
demonstrated for eNOS over-expressing mice (23). Therefore, we decided to employ 
direct stimulation of sGC, the biological target of NO, to stimulate the function of NO-
cGMP pathway in I/R lung injury. This approach enabled activation of the signalling 
pathway as stimulated eNOS would do, without having superoxide and peroxynitrite 
production by uncoupled NOS.  
Direct stimulation of sGC using BAY 41-2272 resulted in substantial sGC stimulation, 
which was confirmed by cGMP measurement. Stimulation of sGC using BAY 41-
2272 protected against permeability disturbances and fluid accumulation in lung 
tissue. BAY 41-2272 might have an immediate effect on the fluid reabsorbtion from 
alveolar space via cGMP gated ion channels. Indeed, recent findings (65, 66) suggest 
that cyclic nucleotide-gated cation channels are an important contributor to adult lung 
fluid homeostasis. 
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Additionally, the protective effect could be explained by observation that NO-cGMP 
signalling pathway interferes with NADPH oxidases by inhibiting assembly (67) and 
by inhibiting expression (40).  
 
4.4 Interaction between NO-cGMP pathway and NADPH oxidase 
Indeed, we observed that BAY 41-2272 inhibited increase in ROS production as well 
as Ppa increase induced by PMA, a stimulator of NADPH oxidase. Moreover, the 
effect of BAY 41-2272 on I/R induced lung injury was comparable with that of 
NADPH oxidase inhibitor apocynin. Consequently, activation of NADPH oxidases 
plays an important role in mediation of I/R injury and the sGC activator exerts its 
effect, at least in part, by prevention of activation of NADPH oxidases. 
Hence, we found that stimulation of sGC by BAY 41-2272 attenuated I/R induced 
lung injury. This protective effect of BAY 41-2272 was achieved by restoration of 
NO-cGMP signalling pathway and preventing activation of NADPH oxidases. 
 
4.5 Conclusion 
Thus, we conclude that iNOS and nNOS contribute to mediation of I/R induced lung 
injury by ROS production. On the other hand, NO-cGMP signalling pathway protects 
against I/R induced lung injury by interfering with activation of NAPDH oxidases.  
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5 SUMMARY 
Ischemia reperfusion (I/R) lung injury is a complex pathological process, which 
occurs in many clinical situations. Previous studies reported equivocal results about 
the role of nitric oxide (NO) synthase isoforms in the mediation of the injury and their 
possible mechanisms of action. Therefore, the aim of our study was to evaluate the 
role of NO synthase isoforms and NO-cGMP signaling pathway on I/R injury of the 
lung in an isolated perfused organ model employing rabbits as well as wild type and 
iNOS and eNOS knock out (KO) mice.  
Lung injury was assessed by measurements of weight gain and microvascular 
permeability (capillary filtration coefficient (Kfc)). Release of reactive oxygen species 
(ROS) into the perfusate was measured during early reperfusion by electron spin 
resonance (ESR) spectroscopy. Unselective NOS inhibitor (L-NMMA), selective 
iNOS inhibitor (1400W, BYK 191023), selective nNOS inhibitor (VNIO), sGC 
stimulator (BAY 41-2272), or NADPH oxidase inhibitor (apocynin) were applied 5 
min before ischemia according to the protocol.  
In untreated lungs dramatic rise in Kfc values and weight gain during reperfusion were 
observed. This was associated with increased reactive oxygen species (ROS) 
production. In rabbit and wild type mouse lungs, unselective NOS and selective iNOS 
or nNOS inhibition protected against I/R injury and was accompanied by reduced 
intravascular ROS release. iNOS and nNOS were upregulated on protein and 
transcript level in the course of I/R. In eNOS and iNOS KO mice the contribution of 
nNOS and iNOS to I/R injury was confirmed. Direct stimulation of sGC using BAY 
41-2272 significantly attenuated vascular leakage and suppressed ROS release. In an 
additional set of experiments BAY 41-2272 diminished phorbol-myristrate-acetate 
(PMA) induced ROS production by NADPH-oxidases. Involvement of ROS generated 
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by NADPH-oxidases in I/R was demonstrated by favorable effects of enzyme 
inhibition by apocynin.  
Thus, we conclude that iNOS and nNOS contribute to mediation of I/R induced lung 
injury by ROS production. On the other hand, NO-cGMP signalling pathway protects 
against I/R induced lung injury by interfering with NAPDH oxidase activation. 
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6 ZUSAMMENFASSUNG 
Der Ischämie/Reperfusionsschaden (I/R) der Lunge ist ein komplexer pathologischer 
Prozess, der im Laufe verschiedener klinischer Situationen, wie Organtransplantation 
und Thrombendarterektomie, auftreten kann. Vorangegangen Studien zeigten 
unterschiedliche Ergebnisse bezüglich der Rolle von NO Synthase-Isoformen bei der 
Vermittlung dieser Art des Lungenschadens. Ziel unserer Studie war es, den Einfluss 
von NO Synthase-Isoformen und des NO-cGMP Signaltransduktionsweges auf den 
I/R Schaden im Modell der isoliert perfundierten und ventilierten Lungen zu 
untersuchen. 
Die Lungenschädigung wurde mittels Gewichtzunahme- und mikrovaskulärer 
Permeabilitätsmessungen (Kfc) quantifiziert. Die Freisetzung von reaktiven 
Sauerstoffspezies (ROS) wurde in rezirkulierendem Puffer mit Beginn der 
Reperfusion mittels Elektronenspinresonanz (ESR)-Technik gemessen. 
Pharmakologische Interventionen wurden mit einem unselektivem NOS Inhibitor 
(L-NMMA), einem selektivem iNOS Inhibitor (1400W, BYK 191023), einem 
selektivem nNOS Inhibitor (VNIO), einem sGC Stimulator (BAY 41-2272) oder 
einem NADPH Oxidasen Inhibitor (Apocynin), welche vor Beginn der Ischämie 
Phase verabreicht wurden, durchgeführt. 
In unbehandelten Lungen konnte ein drastischer Anstieg des Kfc-Wertes, eine 
Gewichtzunahme und eine gesteigerte ROS Produktion nach der Reperfusion 
beobachtet werden. Sowohl in Kaninchen-  als auch in wild-type Mauslungen schützte 
die unselektive NOS-, oder selektive iNOS- und die nNOS-Hemmung vor einem I/R 
Lungenschaden. Dieser Effekt war mit einer reduzierten intravaskulären ROS 
Freisetzung verbunden. Zudem konnte eine erhöhte Protein- und mRNA-Menge der 
iNOS und nNOS Isoformen während I/R beobachtet werden. In iNOS und eNOS 
defizienten Mäusen wurde die Beteiligung der nNOS und iNOS Isoformen am I/R 
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induzierten Lungenschaden bestätigt. Eine direkte sGC-Stimulierung mit BAY 41-
2272 reduzierte den vaskulären Schaden und hemmte die ROS Freisetzung. In 
zusätzlichen Experimenten verminderte BAY 41-2272 die Phorbol-Myristat-Azetat 
(PMA)-induzierte ROS Produktion durch NADPH Oxidasen. Eine Beteiligung der 
von NADPH Oxidasen produzierten ROS an der Entwicklung eines I/R 
Lungenschadens konnte durch eine Inhibierung dieser Schädigung und 
Sauerstoffradikalproduktion mittels Apocynin demonstriert werden. 
Aus diesen Ergebnissen schließen wir, dass sowohl iNOS als auch nNOS über eine 
ROS-Produktion an der Entwicklung eines I/R Lungenschadens beteiligt sind. 
Dagegen zeigt eine direkte Stimulation des NO-cGMP-Signaltransduktionsweges eine 
protektive Wirkung im Hinblick auf eine Reduzierung des I/R Lungenschadens durch 
eine Beeinflussung der NADPH-Oxidase Aktivität. 
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